Maze Therapeutics has appointed Dr Sarah Noonberg as its Chief Financial Officer.

Written by: Nola Cadman
Published on: 21 Oct 2020

Noonberg is a physician-scientist with expertise in global clinical development and corporate strategy, and joins after serving as Chief Medical Officer of Nohla Therapeutics and Prothena Biosciences and the Head of Global Development at BioMarin Pharmaceuticals. Prior to this, she was the Senior Vice President at Medivation, leading translational and early development activities as well as late-stage development of enzalutamide for advanced prostate cancer.

Noonberg also serves on the Board of Directors at Protagonist Therapeutics and Neoleukin Therapeutics.

Dr Jason Coloma, the Chief Executive of Maza, commented on Noonberg’s appointment: “Sarah is an exceptional leader who has helped guide multiple companies through various stages of clinical development and commercialization, and we are thrilled to welcome her to the Maze team. We have been working hard to build an exciting pipeline of potential therapeutics based on targets generated through our platform, and Sarah’s broad experience leading programs from translational research through commercialization for both rare and common diseases will be instrumental. As we take important steps toward entering the clinic and defining our development strategies, we could not be more excited to have her on board and for the future of Maze.”

In terms of education, Noonberg holds an MD from the University of California, San Francisco, and a Ph.D. in bioengineering from the University of California, Berkley, and a BS in engineering science from Dartmouth College.

Noonberg said: “Maze has assembled all of the key ingredients to produce a diverse pipeline of meaningful therapeutics that could significantly impact the treatment of patients with a broad range of diseases. I have been impressed by the company’s approach of leveraging human genetics insights and functional genomics to build an exceptional platform. I look forward to helping lead Maze’s programs through development, and ultimately, bringing them to patients in need.”